Skip to main content
Erschienen in: Osteoporosis International 12/2011

01.12.2011 | Review

Bone health in multiple sclerosis

verfasst von: J. C. Gibson, G. D. Summers

Erschienen in: Osteoporosis International | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

People who are disabled with multiple sclerosis (MS) may be at increased risk of osteoporosis. This review discusses issues relevant to bone health in MS and makes practical recommendations regarding prevention and screening for osteoporosis and fracture risk in MS. A search of the literature up until 5 April 2011 was performed using key search terms, and articles pertinent to bone health in MS were analysed. Bone mineral density (BMD) is reduced at the lumbar spine, hip and total body in MS, with the degree of reduction being greatest at the hip. A strong relationship exists between the disability level, measured by the Expanded Disability Status Score, and BMD at the lumbar spine and femoral neck, particularly the latter. The rate of loss of BMD also correlates with the level of disability. Pulsed corticosteroids for acute episodes of MS, even with a high cumulative steroid dose, do not significantly affect BMD, but an effect on fracture risk is yet to be elucidated. There appears to be no correlation between vitamin D levels and BMD, and the relationship between disability and vitamin D levels remains unclear. Falls and fractures are more common than in healthy controls, and the risk rises with increasing levels of disability. The principal factor resulting in low BMD and increased fracture risk in MS is immobility. Antiresorptive therapy with bisphosphonates and optimising vitamin D levels are likely to be effective interventions although there are no randomised studies of this therapy.
Literatur
2.
Zurück zum Zitat National Institute for Clinical Excellence (2003) Multiple sclerosis: management of multiple sclerosis in primary and secondary care. National Institute for Clinical Excellence, London National Institute for Clinical Excellence (2003) Multiple sclerosis: management of multiple sclerosis in primary and secondary care. National Institute for Clinical Excellence, London
3.
Zurück zum Zitat Steffensen LH, Jorgensen L, Straume B, Mellgren SI, Kampman MT (2011) Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol (in press) Steffensen LH, Jorgensen L, Straume B, Mellgren SI, Kampman MT (2011) Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol (in press)
4.
Zurück zum Zitat Francis J, Gaywood I (2009) A cross-sectional study of bone health in multiple sclerosis Francis J, Gaywood I (2009) A cross-sectional study of bone health in multiple sclerosis
5.
Zurück zum Zitat Havrdova E, Tyblova M, Stepan JJ, Zikan V, Horakova D, Ticha V, Novakova I (2002) Osteoporosis in multiple sclerosis patients treated with corticosteroids. Mult Scler 8:S79 Havrdova E, Tyblova M, Stepan JJ, Zikan V, Horakova D, Ticha V, Novakova I (2002) Osteoporosis in multiple sclerosis patients treated with corticosteroids. Mult Scler 8:S79
6.
Zurück zum Zitat Hotermans C, Dive D, Rinkin, Leroy M, Malaise M, Moonen G, Franchimont N (2006) Hip bone mineral density is correlated with EDSS in patients with multiple sclerosis. J Neurol 257(3):410–418 Hotermans C, Dive D, Rinkin, Leroy M, Malaise M, Moonen G, Franchimont N (2006) Hip bone mineral density is correlated with EDSS in patients with multiple sclerosis. J Neurol 257(3):410–418
7.
Zurück zum Zitat Gallagher E, Epstein S, Weppner D, Wrest K, Weinstock-Guttman B, Brownscheidle C, Patrick K, Jacobs L (2002) Bone loss in women with multiple sclerosis. International Journal of MS Care 4:3 Gallagher E, Epstein S, Weppner D, Wrest K, Weinstock-Guttman B, Brownscheidle C, Patrick K, Jacobs L (2002) Bone loss in women with multiple sclerosis. International Journal of MS Care 4:3
8.
Zurück zum Zitat Cosman F, Nieves J, Komar L, Ferrer G, Herbert J et al (1998) Fracture history and bone loss in patients with MS. Neurology 51:1161–1165PubMed Cosman F, Nieves J, Komar L, Ferrer G, Herbert J et al (1998) Fracture history and bone loss in patients with MS. Neurology 51:1161–1165PubMed
9.
Zurück zum Zitat Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroid. Mult Scler 9:600–604PubMedCrossRef Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroid. Mult Scler 9:600–604PubMedCrossRef
10.
Zurück zum Zitat Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y (2005) Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23:309–313PubMedCrossRef Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y (2005) Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23:309–313PubMedCrossRef
11.
Zurück zum Zitat Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R (1997) Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 61:129–133PubMedCrossRef Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R (1997) Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 61:129–133PubMedCrossRef
12.
Zurück zum Zitat Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12:550–556PubMedCrossRef Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12:550–556PubMedCrossRef
13.
Zurück zum Zitat Terzi T, Terzi M, Tander B, Canturk F, Onar M (2010) Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 17:1260–1264PubMedCrossRef Terzi T, Terzi M, Tander B, Canturk F, Onar M (2010) Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 17:1260–1264PubMedCrossRef
14.
Zurück zum Zitat Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89:4923–4928PubMedCrossRef Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89:4923–4928PubMedCrossRef
15.
Zurück zum Zitat Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687–1692PubMed Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687–1692PubMed
16.
Zurück zum Zitat Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M (2004) Risk of bone loss in men with multiple sclerosis. Mult Scler 10:170–175PubMedCrossRef Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M (2004) Risk of bone loss in men with multiple sclerosis. Mult Scler 10:170–175PubMedCrossRef
17.
Zurück zum Zitat Mojtahedi MC, Snook EM, Motl RW, Evans EM (2008) Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev 45:851–861PubMedCrossRef Mojtahedi MC, Snook EM, Motl RW, Evans EM (2008) Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev 45:851–861PubMedCrossRef
18.
Zurück zum Zitat Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM (2009) Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 178:43–45PubMedCrossRef Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM (2009) Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 178:43–45PubMedCrossRef
19.
Zurück zum Zitat Schwid SR, Goodman AD, Edward PJ, McDermott MP, Mattson DH (1996) Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 53:753–757PubMed Schwid SR, Goodman AD, Edward PJ, McDermott MP, Mattson DH (1996) Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 53:753–757PubMed
20.
Zurück zum Zitat El-Ghoneimy AT, Gad AH, Samir H, Shalaby NM (2009) Contribution of vitamin D to the pathogenesis of multiple sclerosis and its effect on bone. Egyptian Journal of Neurology, Psychiatry and Neurosurgery 46:209–222 El-Ghoneimy AT, Gad AH, Samir H, Shalaby NM (2009) Contribution of vitamin D to the pathogenesis of multiple sclerosis and its effect on bone. Egyptian Journal of Neurology, Psychiatry and Neurosurgery 46:209–222
21.
Zurück zum Zitat Proctor DN, Melton LJ, Khosla S, Crowson CS, O’Connor MK, Riggs BL (2000) Relative influence of physical activity, muscle mass and strength on bone density. Osteoporos Int 11:944–952PubMedCrossRef Proctor DN, Melton LJ, Khosla S, Crowson CS, O’Connor MK, Riggs BL (2000) Relative influence of physical activity, muscle mass and strength on bone density. Osteoporos Int 11:944–952PubMedCrossRef
22.
Zurück zum Zitat Lambert CP, Lee AR, Evans WJ (2002) Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 83:1559–1561PubMedCrossRef Lambert CP, Lee AR, Evans WJ (2002) Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 83:1559–1561PubMedCrossRef
23.
Zurück zum Zitat Stepan JJ, Havrdova E, Tyblova M, Horakova D, Ticha V, Novakova I, Zikan V (2004) Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta 348:147–154PubMedCrossRef Stepan JJ, Havrdova E, Tyblova M, Horakova D, Ticha V, Novakova I, Zikan V (2004) Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta 348:147–154PubMedCrossRef
24.
Zurück zum Zitat Sabo D, Blaich S, Wenz W, Hohmann M, Loew M, Gerner HJ (2001) Osteoporosis in patients with paralysis after spinal cord injury. A cross sectional study in 46 male patients with dual-energy X-ray absorptiometry. Arch Orthop Trauma Surg 121:75–78PubMedCrossRef Sabo D, Blaich S, Wenz W, Hohmann M, Loew M, Gerner HJ (2001) Osteoporosis in patients with paralysis after spinal cord injury. A cross sectional study in 46 male patients with dual-energy X-ray absorptiometry. Arch Orthop Trauma Surg 121:75–78PubMedCrossRef
25.
Zurück zum Zitat Slade JM, Bickel CS, Modlesky CM, Majumdar S, Dudley GA (2005) Trabecular bone is more deteriorated in spinal cord injured versus estrogen-free postmenopausal women. Osteoporos Int 16:263–272PubMedCrossRef Slade JM, Bickel CS, Modlesky CM, Majumdar S, Dudley GA (2005) Trabecular bone is more deteriorated in spinal cord injured versus estrogen-free postmenopausal women. Osteoporos Int 16:263–272PubMedCrossRef
26.
Zurück zum Zitat Jiang SD, Dai LY, Jiang LS (2006) Osteoporosis after spinal cord injury. Osteoporos Int 17:180–192PubMedCrossRef Jiang SD, Dai LY, Jiang LS (2006) Osteoporosis after spinal cord injury. Osteoporos Int 17:180–192PubMedCrossRef
27.
Zurück zum Zitat Pang MY, Eng JJ, McKay HA, Dawson AS (2005) Reduced hip bone mineral density is related to physical fitness and leg lean mass in ambulatory individuals with chronic stroke. Osteoporos Int 16:1769–1779PubMedCrossRef Pang MY, Eng JJ, McKay HA, Dawson AS (2005) Reduced hip bone mineral density is related to physical fitness and leg lean mass in ambulatory individuals with chronic stroke. Osteoporos Int 16:1769–1779PubMedCrossRef
28.
Zurück zum Zitat Jorgensen L, Jacobsen BK, Wilsgaard T, Magnus JH (2000) Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos Int 11:381–387PubMedCrossRef Jorgensen L, Jacobsen BK, Wilsgaard T, Magnus JH (2000) Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos Int 11:381–387PubMedCrossRef
29.
Zurück zum Zitat Del PA, Pappone N, Mandes MG, Mantova D, Scarpa R, Oriente P (1996) Determinants of bone mineral density in immobilization: a study on hemiplegic patients. Osteoporos Int 6:50–54CrossRef Del PA, Pappone N, Mandes MG, Mantova D, Scarpa R, Oriente P (1996) Determinants of bone mineral density in immobilization: a study on hemiplegic patients. Osteoporos Int 6:50–54CrossRef
30.
Zurück zum Zitat Stenager E, Jensen K (1991) Fractures in multiple sclerosis. Acta Neurol Belg 91:296–302PubMed Stenager E, Jensen K (1991) Fractures in multiple sclerosis. Acta Neurol Belg 91:296–302PubMed
31.
Zurück zum Zitat Peterson EW, Cho CC, von KL, Finlayson ML (2008) Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 89:1031–1037PubMedCrossRef Peterson EW, Cho CC, von KL, Finlayson ML (2008) Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 89:1031–1037PubMedCrossRef
32.
Zurück zum Zitat Troiano RA, Jotkowitz A, Cook SD, Bansil S, Zito G (1992) Rate and types of fractures in corticosteroid-treated multiple sclerosis patients. Neurology 42:1389–1391PubMed Troiano RA, Jotkowitz A, Cook SD, Bansil S, Zito G (1992) Rate and types of fractures in corticosteroid-treated multiple sclerosis patients. Neurology 42:1389–1391PubMed
33.
Zurück zum Zitat Williams P, Frank A, Crawford CM et al (1984) Unrecongised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J 189:501CrossRef Williams P, Frank A, Crawford CM et al (1984) Unrecongised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J 189:501CrossRef
34.
Zurück zum Zitat Aggarwal A, Parvizi J, Ganz R (2004) Bilateral spontaneous periacetabular fracture: an unusual complication of multiple sclerosis. J Orthop Trauma 18:182–185PubMedCrossRef Aggarwal A, Parvizi J, Ganz R (2004) Bilateral spontaneous periacetabular fracture: an unusual complication of multiple sclerosis. J Orthop Trauma 18:182–185PubMedCrossRef
35.
Zurück zum Zitat Cocksedge S, Freestone S, Martin JF (1984) Unrecognised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J Clin Res Ed 289:309PubMedCrossRef Cocksedge S, Freestone S, Martin JF (1984) Unrecognised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J Clin Res Ed 289:309PubMedCrossRef
36.
Zurück zum Zitat Logan WC Jr, Sloane R, Lyles KW, Goldstein B, Hoenig HM (2008) Incidence of fractures in a cohort of veterans with chronic multiple sclerosis or traumatic spinal cord injury. Arch Phys Med Rehabil 89:237–243PubMedCrossRef Logan WC Jr, Sloane R, Lyles KW, Goldstein B, Hoenig HM (2008) Incidence of fractures in a cohort of veterans with chronic multiple sclerosis or traumatic spinal cord injury. Arch Phys Med Rehabil 89:237–243PubMedCrossRef
37.
Zurück zum Zitat Sibley WA, Bamford CR, Clark K, Smith MS, Laguna JF (1991) A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 54:584–589PubMedCrossRef Sibley WA, Bamford CR, Clark K, Smith MS, Laguna JF (1991) A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 54:584–589PubMedCrossRef
38.
Zurück zum Zitat Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ (2008) The epidemiology of fractures in England. J Epidemiol Community Health 62:174–180PubMedCrossRef Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ (2008) The epidemiology of fractures in England. J Epidemiol Community Health 62:174–180PubMedCrossRef
39.
Zurück zum Zitat Marrie RA, Cutter G, Tyry T, Vollmer T (2009) A cross-sectional study of bone health in multiple sclerosis. Neurology 73:1394–1398PubMedCrossRef Marrie RA, Cutter G, Tyry T, Vollmer T (2009) A cross-sectional study of bone health in multiple sclerosis. Neurology 73:1394–1398PubMedCrossRef
40.
Zurück zum Zitat Bazelier M, van Staa T, Leufkens H, Vestergaard P, Cooper C, Uitdehaag B, Lalmohamed A, de Vries F (2010) Risk of fracture in patients with multiple sclerosis: a population-based cohort study. Osteoporos Int 21:S450–S451 Bazelier M, van Staa T, Leufkens H, Vestergaard P, Cooper C, Uitdehaag B, Lalmohamed A, de Vries F (2010) Risk of fracture in patients with multiple sclerosis: a population-based cohort study. Osteoporos Int 21:S450–S451
41.
Zurück zum Zitat Finlayson ML, Peterson EW, Cho CC (2006) Risk factors for falling among people aged 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil 87:1274–1279PubMedCrossRef Finlayson ML, Peterson EW, Cho CC (2006) Risk factors for falling among people aged 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil 87:1274–1279PubMedCrossRef
42.
Zurück zum Zitat Cattaneo D, De NC, Fascia T, Macalli M, Pisoni I, Cardini R (2002) Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 83:864–867PubMedCrossRef Cattaneo D, De NC, Fascia T, Macalli M, Pisoni I, Cardini R (2002) Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 83:864–867PubMedCrossRef
43.
Zurück zum Zitat Kirby RL, Ackroyd-Stolarz SA, Brown MG, Kirkland SA, MacLeod DA (1994) Wheelchair-related accidents caused by tips and falls among noninstitutionalised users of manually propelled wheelchairs in Nova Scotia. Am J Phys Med Rehabil 73:319–330PubMedCrossRef Kirby RL, Ackroyd-Stolarz SA, Brown MG, Kirkland SA, MacLeod DA (1994) Wheelchair-related accidents caused by tips and falls among noninstitutionalised users of manually propelled wheelchairs in Nova Scotia. Am J Phys Med Rehabil 73:319–330PubMedCrossRef
44.
Zurück zum Zitat Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG (2009) Predicting accidental falls in people with multiple sclerosis—a longitudinal study. Clin Rehabil 23:259–269PubMedCrossRef Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG (2009) Predicting accidental falls in people with multiple sclerosis—a longitudinal study. Clin Rehabil 23:259–269PubMedCrossRef
45.
Zurück zum Zitat Cattaneo D, DeNuzzo C, Fascia T, Macalli M, Pisoni I, Cardoni R (2002) Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 83:864–867PubMedCrossRef Cattaneo D, DeNuzzo C, Fascia T, Macalli M, Pisoni I, Cardoni R (2002) Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 83:864–867PubMedCrossRef
46.
Zurück zum Zitat Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH, Bassey EJ (1988) Falls by elderly people at home: prevalence and associated factors. Age Ageing 17:365–372PubMedCrossRef Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH, Bassey EJ (1988) Falls by elderly people at home: prevalence and associated factors. Age Ageing 17:365–372PubMedCrossRef
47.
Zurück zum Zitat O’Loughlin JL, Robitaille Y, Boivin JF, Suissa S (1993) Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol 137:342–354PubMed O’Loughlin JL, Robitaille Y, Boivin JF, Suissa S (1993) Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol 137:342–354PubMed
48.
Zurück zum Zitat Tinetti ME, Speechley M, Ginter SF (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701–1707PubMedCrossRef Tinetti ME, Speechley M, Ginter SF (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701–1707PubMedCrossRef
49.
Zurück zum Zitat Cameron MH, Poel AJ, Haselkorn JK, Linke A, Bourdette D (2011) Falls requiring medical attention among veterans with multiple sclerosis: a cohort study. J Rehabil Res Dev 48:13–20PubMedCrossRef Cameron MH, Poel AJ, Haselkorn JK, Linke A, Bourdette D (2011) Falls requiring medical attention among veterans with multiple sclerosis: a cohort study. J Rehabil Res Dev 48:13–20PubMedCrossRef
50.
Zurück zum Zitat Ardissone P, Rota E, Durelli L, Limone P, Isaia GC (2002) Effects of high doses of corticosteroids on bone metabolism. J Endocrinol Investig 25:129–133 Ardissone P, Rota E, Durelli L, Limone P, Isaia GC (2002) Effects of high doses of corticosteroids on bone metabolism. J Endocrinol Investig 25:129–133
51.
Zurück zum Zitat Cosman F, Nieves J, Herbert J, Shen V, Lindsay R (1994) High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 9:1097–1105PubMedCrossRef Cosman F, Nieves J, Herbert J, Shen V, Lindsay R (1994) High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 9:1097–1105PubMedCrossRef
52.
Zurück zum Zitat Bergh FT, Kumpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismuller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP (2006) Monthly intravenous methylprednisolone in relapsing–remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 6:19CrossRef Bergh FT, Kumpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismuller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP (2006) Monthly intravenous methylprednisolone in relapsing–remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 6:19CrossRef
53.
Zurück zum Zitat Steffensen LH, Mellgren SI, Kampman MT (2010) Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 257:410–418PubMedCrossRef Steffensen LH, Mellgren SI, Kampman MT (2010) Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 257:410–418PubMedCrossRef
54.
Zurück zum Zitat Achiron A, Edelstein S, Ziev-Ner Y, Givon U, Rotstein Z, Barak Y (2004) Bone strength in multiple sclerosis: Cortical midtibial speed-of-sound assessment. Mult Scler 10:488–493PubMedCrossRef Achiron A, Edelstein S, Ziev-Ner Y, Givon U, Rotstein Z, Barak Y (2004) Bone strength in multiple sclerosis: Cortical midtibial speed-of-sound assessment. Mult Scler 10:488–493PubMedCrossRef
55.
Zurück zum Zitat Frediani B, Falsetti P, Bisogno S, Baldi F, Acciai C, Filippou G, Bacarelli MR, Filipponi P, Galeazzi M, Marcolongo R (2004) Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 31:1083–1087PubMed Frediani B, Falsetti P, Bisogno S, Baldi F, Acciai C, Filippou G, Bacarelli MR, Filipponi P, Galeazzi M, Marcolongo R (2004) Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 31:1083–1087PubMed
56.
Zurück zum Zitat Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedCrossRef Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedCrossRef
57.
Zurück zum Zitat Van Staa TP, Geusens P, Pols HA, De LC, Leufkens HG, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191–198PubMedCrossRef Van Staa TP, Geusens P, Pols HA, De LC, Leufkens HG, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191–198PubMedCrossRef
58.
Zurück zum Zitat Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389CrossRef Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389CrossRef
59.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2008) Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 82:249–257PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2008) Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 82:249–257PubMedCrossRef
60.
Zurück zum Zitat Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRef Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRef
61.
Zurück zum Zitat de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRef de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRef
62.
Zurück zum Zitat Institute of Medicine of the National Academies (2010) Dietary reference intakes for calcium and vitamin D. In: Ross CA, Taylor AL, Yaktine AL, Del Valle HB (eds) National Academies Press, Washington, DC, p 1132 Institute of Medicine of the National Academies (2010) Dietary reference intakes for calcium and vitamin D. In: Ross CA, Taylor AL, Yaktine AL, Del Valle HB (eds) National Academies Press, Washington, DC, p 1132
63.
Zurück zum Zitat Simmons RD, Ponsonby A-L, van der Mei IA, Sheridan P (2004) What affects your MS? Responses to an anonymous, internet-based epidemiological survey. Mult Scler 10:202–211PubMedCrossRef Simmons RD, Ponsonby A-L, van der Mei IA, Sheridan P (2004) What affects your MS? Responses to an anonymous, internet-based epidemiological survey. Mult Scler 10:202–211PubMedCrossRef
64.
Zurück zum Zitat Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79:152–157PubMedCrossRef Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79:152–157PubMedCrossRef
65.
Zurück zum Zitat Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, Kerr D, Greenberg BM, Calabresi PA (2009) Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 15:735–740PubMedCrossRef Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, Kerr D, Greenberg BM, Calabresi PA (2009) Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 15:735–740PubMedCrossRef
66.
Zurück zum Zitat van der Mei IA, Ponsonby A-L, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581–590PubMedCrossRef van der Mei IA, Ponsonby A-L, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581–590PubMedCrossRef
67.
Zurück zum Zitat Barnes MS, Bonham MP, Robson PJ, Strain JJ, Lowe-Strong AS, Eaton-Evans J, Ginty F, Wallace JM (2007) Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 13:670–672PubMedCrossRef Barnes MS, Bonham MP, Robson PJ, Strain JJ, Lowe-Strong AS, Eaton-Evans J, Ginty F, Wallace JM (2007) Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 13:670–672PubMedCrossRef
68.
Zurück zum Zitat Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11:266–271PubMedCrossRef Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11:266–271PubMedCrossRef
69.
Zurück zum Zitat Kragt J, van AB, Killestein J, Dijkstra C, Uitdehaag B, Polman C, Lips P (2009) Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 15:9–15PubMedCrossRef Kragt J, van AB, Killestein J, Dijkstra C, Uitdehaag B, Polman C, Lips P (2009) Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 15:9–15PubMedCrossRef
70.
Zurück zum Zitat Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132:1146–1160PubMedCrossRef Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132:1146–1160PubMedCrossRef
71.
Zurück zum Zitat Varoglu AO, Varoglu E, Bayraktar R, Aygul R, Ulvi H, Yildirim K (2010) The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients. J Back Musculoskelet Rehabil 23:25–29PubMed Varoglu AO, Varoglu E, Bayraktar R, Aygul R, Ulvi H, Yildirim K (2010) The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients. J Back Musculoskelet Rehabil 23:25–29PubMed
72.
Zurück zum Zitat Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409PubMedCrossRef Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409PubMedCrossRef
73.
Zurück zum Zitat Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L (2004) Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 155:155–160PubMedCrossRef Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L (2004) Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 155:155–160PubMedCrossRef
74.
Zurück zum Zitat Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas NJ, Rio J, Montalban X (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158:231–239PubMedCrossRef Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas NJ, Rio J, Montalban X (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158:231–239PubMedCrossRef
75.
Zurück zum Zitat Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S (2009) The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 276:41–44PubMedCrossRef Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S (2009) The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 276:41–44PubMedCrossRef
76.
Zurück zum Zitat Shabas D, Weinreb H (2000) Preventive healthcare in women with multiple sclerosis. J Womens Health Gend-Based Med 9:389–396PubMedCrossRef Shabas D, Weinreb H (2000) Preventive healthcare in women with multiple sclerosis. J Womens Health Gend-Based Med 9:389–396PubMedCrossRef
77.
Zurück zum Zitat Sharts-Hopko NC, Sullivan MP (2002) Beliefs, perceptions, and practices related to osteoporosis risk reduction among women with multiple sclerosis. Rehabil Nurs 27:232–237PubMed Sharts-Hopko NC, Sullivan MP (2002) Beliefs, perceptions, and practices related to osteoporosis risk reduction among women with multiple sclerosis. Rehabil Nurs 27:232–237PubMed
78.
Zurück zum Zitat Sharts-Hopko NC, Smelter S (2004) Perceptions of women with multiple sclerosis about osteoporosis follow-up. J Neurosci Nurs 36:189–194PubMedCrossRef Sharts-Hopko NC, Smelter S (2004) Perceptions of women with multiple sclerosis about osteoporosis follow-up. J Neurosci Nurs 36:189–194PubMedCrossRef
79.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMed
80.
Zurück zum Zitat Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438PubMedCrossRef Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438PubMedCrossRef
81.
Zurück zum Zitat Trojano M, Paolicelli D, Bellacosa A, Cataldo S (2003) The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 24(Suppl 5):S268–S270PubMedCrossRef Trojano M, Paolicelli D, Bellacosa A, Cataldo S (2003) The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 24(Suppl 5):S268–S270PubMedCrossRef
82.
Zurück zum Zitat Leray E, Yaouanq J, Le PE, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913PubMedCrossRef Leray E, Yaouanq J, Le PE, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913PubMedCrossRef
83.
Zurück zum Zitat Cakt BD, Nacir B, Genc H, Saracoglu M, Karagoz A, Erdem HR, Ergun U (2010) Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 89:446–457PubMedCrossRef Cakt BD, Nacir B, Genc H, Saracoglu M, Karagoz A, Erdem HR, Ergun U (2010) Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 89:446–457PubMedCrossRef
84.
Zurück zum Zitat Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T (2009) Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73:1478–1484PubMedCrossRef Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T (2009) Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73:1478–1484PubMedCrossRef
85.
Zurück zum Zitat Stroud NM, Minahan CL (2009) The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis. Health Qual Life Outcomes 7:68PubMedCrossRef Stroud NM, Minahan CL (2009) The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis. Health Qual Life Outcomes 7:68PubMedCrossRef
86.
Zurück zum Zitat Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention 1. Age Ageing 35(Suppl 2):ii37–ii41PubMedCrossRef Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention 1. Age Ageing 35(Suppl 2):ii37–ii41PubMedCrossRef
87.
Zurück zum Zitat Snook EM, Motl RW (2009) Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair 23:108–116PubMed Snook EM, Motl RW (2009) Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair 23:108–116PubMed
88.
Zurück zum Zitat Bischoff-Ferrari HA (2007) How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18:401–407PubMedCrossRef Bischoff-Ferrari HA (2007) How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18:401–407PubMedCrossRef
89.
Zurück zum Zitat Musso C, Liakopoulos V, Pangre N, DiTrolio J, Jauregui R, De MR, Stefanidis I, Imperiali N, Algranati L (2009) Renal physiology in elderly persons with severe immobility syndrome. Int Urol Nephrol 41:437–441PubMedCrossRef Musso C, Liakopoulos V, Pangre N, DiTrolio J, Jauregui R, De MR, Stefanidis I, Imperiali N, Algranati L (2009) Renal physiology in elderly persons with severe immobility syndrome. Int Urol Nephrol 41:437–441PubMedCrossRef
90.
Zurück zum Zitat Poole KE, Reeve J, Warburton EA (2002) Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke 33:1432–1436PubMedCrossRef Poole KE, Reeve J, Warburton EA (2002) Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke 33:1432–1436PubMedCrossRef
91.
Zurück zum Zitat Sato Y, Iwamoto J, Kanoko T, Satoh K (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 21:924–929PubMedCrossRef Sato Y, Iwamoto J, Kanoko T, Satoh K (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 21:924–929PubMedCrossRef
92.
Zurück zum Zitat Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi AH (2010) Oropharyngeal dysphagia in multiple sclerosis. Mult Scler 16:362–365PubMedCrossRef Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi AH (2010) Oropharyngeal dysphagia in multiple sclerosis. Mult Scler 16:362–365PubMedCrossRef
93.
Zurück zum Zitat Herndon RM, Mohandas N (2000) Osteoporosis in multiple sclerosis: a frequent, serious, and under-recognized problem. In J MS Care 2:5–12 Herndon RM, Mohandas N (2000) Osteoporosis in multiple sclerosis: a frequent, serious, and under-recognized problem. In J MS Care 2:5–12
94.
Zurück zum Zitat Edlich RF, Mason SS, Reddig JS, Gubler K, Long WB III (2010) A case report: femoral fracture in a multiple sclerosis patient with vitamin D deficiency—a preventable injury. J Environ Pathol Toxicol Oncol 29:3–5PubMed Edlich RF, Mason SS, Reddig JS, Gubler K, Long WB III (2010) A case report: femoral fracture in a multiple sclerosis patient with vitamin D deficiency—a preventable injury. J Environ Pathol Toxicol Oncol 29:3–5PubMed
Metadaten
Titel
Bone health in multiple sclerosis
verfasst von
J. C. Gibson
G. D. Summers
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 12/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1644-8

Weitere Artikel der Ausgabe 12/2011

Osteoporosis International 12/2011 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.